Explore

Bank of America Invests Over $250 Million Annually in Employee GLP-1 Drugs

Bank of America Invests Over $250 Million Annually in Employee GLP-1 Drugs

Bank of America Invests Over $250 Million Annually in Employee GLP-1 Drugs

Bank of America Allocates Over $250 Million Annually for Employee Weight-Loss Drugs

Bank of America Allocates Over $250 Million Annually for Employee Weight-Loss Drugs

Bank of America Allocates Over $250 Million Annually for Employee Weight-Loss Drugs

Bank of America Invests Over $250 Million Annually in Employee Obesity Treatments

Bank of America Invests Over $250 Million Annually in Employee Obesity Treatments

Bank of America Invests Over $250 Million Annually in Employee Obesity Treatments

Bank of America Invests $250 Million Annually in Employee Health with GLP-1 Drugs

Bank of America Invests $250 Million Annually in Employee Health with GLP-1 Drugs

Bank of America Invests $250 Million Annually in Employee Health with GLP-1 Drugs

Bank of America spends $250M yearly on GLP-1s for workers, CEO says

Bank of America spends $250M yearly on GLP-1s for workers, CEO says

Bank of America's CEO said the company spends more than $250 million a year on GLP-1 drugs for employees, calling the growing cost a worthwhile investment.

Bank of America Invests $250 Million Annually in GLP-1 Weight-Loss Medications for Employees

Bank of America Invests $250 Million Annually in GLP-1 Weight-Loss Medications for Employees

Bank of America Invests $250 Million Annually in GLP-1 Weight-Loss Medications for Employees

Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health

Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health

Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health

Bank of America Continues $250 Million Investment in Employee Weight-Loss Medications

Bank of America Continues $250 Million Investment in Employee Weight-Loss Medications

Bank of America Continues $250 Million Investment in Employee Weight-Loss Medications

Bank of America Commits $250 Million Annually to Employee Weight-Loss Medication

Bank of America Commits $250 Million Annually to Employee Weight-Loss Medication

Bank of America Commits $250 Million Annually to Employee Weight-Loss Medication

Starbucks Ends GLP-1 Coverage for Weight Loss Amid Rising Costs

Starbucks Ends GLP-1 Coverage for Weight Loss Amid Rising Costs

Starbucks Ends GLP-1 Coverage for Weight Loss Amid Rising Costs

Novo Nordisk CEO resets expectations for Wegovy's explosive growth

Novo Nordisk CEO resets expectations for Wegovy's explosive growth

I believe that when a stock is down nearly 10% year to date and down 38% over three years, the CEO's job on a quarterly earnings call is not just to report results. It is to rebuild a narrative that investors have lost confidence in. And Novo Nordisk CEO Mike Doustdar is honestly trying that with ...

Novo Nordisk CEO Resets Expectations for Wegovy's Growth Amid Market Competition

Novo Nordisk CEO Resets Expectations for Wegovy's Growth Amid Market Competition

Novo Nordisk CEO Resets Expectations for Wegovy's Growth Amid Market Competition